IMV Inc.
IMVIF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$19.12K
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $19,120.00 |
|---|---|
| Enterprise Value | $7.69 Million |
| Earnings per Share | $-4.37 |
| Beta | 0.3 |
| Outstanding Shares | 9,560,222 |
Return
| Return on Equity | 554.67% |
|---|---|
| Return on Assets | -116.81% |
| Return on Invested Capital | -175.43% |
Valuation & Multiples
| P/E Ratio | -0.18 |
|---|---|
| PEG | 0.61 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.2 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 3.76 |
| Debt to Equity | -4.38 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
$-1.27
Consensus analyst estimateRevenue Estimate
$34,477
Consensus analyst estimateNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-1.27
Consensus analyst estimateRevenue Estimate
$34,477
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About IMV Inc
63 employees
CEO: Andrew Hall
IMV Inc. is a biopharmaceutical firm focused on immuno-oncology, currently in the clinical development stage. The company leverages its proprietary DPX immune-modulating platform to create a diverse range of treatments aimed at both soli...